BTG Share PerformanceMore
|52 week high||739.5 12/07/16|
|52 week low||528.4 31/01/17|
|52 week change||-40.5 (-6.05%)|
|4 week volume||22,105,802 29/04/17|
Latest News« previous» nextMore
22/05/2017 - 13:03 StockMarketWire
BTG (LSE: BTG) has highlighted the results of the OPTALYSE PE trial, presented at the American Thoracic Society Intern...
22/05/2017 - 12:00 RNS
RNS Number: 8184F BTG PLC 22 May 2017 OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS Therapy For Pulmonary Embolism Bothell, WA, 22 May 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the OPTALYSE PE trial, presented at the American Thoracic Society Internati...
19/05/2017 - 12:10 StockMarketWire
Panmure Gordon today reaffirms its buy investment rating on BTG PLC (LON:BTG) and cut its price target to 793p (from...
18/05/2017 - 13:26 Interactive Investor
If you're looking for capital growth, don't bother with big pharma, argues fund manager Paul Mumford. He tells Lee Wild...
17/05/2017 - 12:10 StockMarketWire
Peel Hunt today reaffirms its hold investment rating on BTG PLC (LON:BTG) and raised its price target to 680p (from 630...
17/05/2017 - 09:59 RNS
RNS Number: 4166F BTG PLC 17 May 2017 17 May 2017 BTG plc - Additional Listing BTG plc (LSE:BTG) announces that application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 650,000 ordinary shares of 10 pence each under the BTG Performance Share Plan, 21,000 ordinary shares of 10 pence each under the BTG...
17/05/2017 - 09:30 StockMarketWire
JP Morgan Cazenove today reaffirms its neutral investment rating on BTG PLC (LON:BTG) and cut its price target to 750...
16/05/2017 - 12:00 StockMarketWire
Panmure Gordon today reaffirms its buy investment rating on BTG PLC (LON:BTG) and raised its price target to 809p (fr...
|Dividend yield||0 %|
Equity Research (BTG)
Growth across all three divisions of BTG’s Interventional Medicine (IM) franchise (oncology, vascular and pulmonology), coupled with currency tailwinds, helped push FY16 revenue towards the upper end...
BTG’s interim results have driven upgrades to our financial forecasts with a small boost to revenues from one-off Zytiga backdated royalties. Our operating expenses are broadly unchanged, but...
BTG’s close period update saw a revision to its FY16 revenue guidance, targeting sales in the lower half of £410-440m (at $1.61/£). This is based on slower-than-expected Varithena sales, despite a...
- 1 of 3
Latest discussion posts More
“The stock is not going anywhere until the recent acquisitions and varithena for faty people takes off. Institions will hold then sell out . INMO the thing to look for is ...”▼
“OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS? Therapy For Pulmonary Embolism Bothell, WA, 22 May 2017: BTG plc (LSE: BTG), the global ...”▼
“So we go up and then as Usaul we drip down !! Is this the most frautrauting share ever ?? Me De Gasser et al have held for over 10 years !! Yes we bought in at 70p and no ...”▼
Codes & Symbols
|Symbols||BTG, LSE:BTG, BTG.L, BTG:LN, LON:BTG, XLON:BTG|